Evidence map›Paper›PMID 17581613›Full record

Trial reportLeukemia2007

Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma.

S Kumar, A Dispenzieri, M Q Lacy, S R Hayman, F K Buadi, D A Gastineau, M R Litzow, R Fonseca, V Roy, S V Rajkumar and 1 more

Registry-linked trialAbstract readClinical TrialComparative Study
PubMed Publisher
In one paragraph

Trial report in Leukemia, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01095757 (Evaluation of Plerixafor), which is not on this map. Cited by 135 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
135citing papers in PubMed, 4 pooled it
12.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01095757 phase2completednot on this mapstarted 2010, after this paper: background citation

Evaluation of Plerixafor (Mozobil ™, AMD3100) in Combination With Chemotherapy and G-CSF for CD34+ Cell Mobilization

TypeinterventionalSponsorEmory UniversityRan2010 to 2014Enrolled45ConditionsMyeloma, LymphomaArmsPlerixafor
3 · Its place in the literature

Who cites it

135 citing papers in PubMed, 4 syntheses or guidelines pooled it, 349 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Multiple Myeloma, Version 2.2016: Clinical Practice Guidelines in Oncology.Journal of the National Comprehensive Cancer Network : JNCCN · 2015
    Guideline
  4. Guideline
  5. Trial
  6. Trial
  7. Trial
  8. Plerixafor Plus Granulocyte Colony-Stimulating Factor for Patients with Non-Hodgkin Lymphoma and Multiple Myeloma: Long-Term Follow-Up Report.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2018
    Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2008
    Trial

75 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

S KumarDivisions of Hematology, Mayo Clinic, Rochester, MN, USA. kumar.shaji@mayo.edu
A Dispenzieri
M Q Lacy
S R Hayman
F K Buadi
D A Gastineau
M R Litzow
R Fonseca
V Roy
S V Rajkumar
M A Gertz
Mayo Clinic · USMayo Clinic in Arizona · USWinnMed · USMayo Clinic in Florida · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

While initial therapies have become highly effective with introduction of lenalidomide and bortezomib and patients may opt for delayed stem cell transplantation, it is important to collect stem cells for future transplant. Given its increasing use as initial therapy, we examined if lenalidomide had any impact on the ability to collect peripheral blood stem cells (PBSC). We studied the entire cohort of patients with myeloma undergoing PBSC mobilization at our institution during a 5-year period, comparing the results between patients receiving different initial therapies. Among those mobilized with granulocyte-colony stimulating factor (G-CSF) alone, there was a significant decrease in total CD34(+) cells collected (P<0.001), average daily collection (P<0.001), day 1 collection (P<0.001) and increased number of aphereses (P=0.004) in patients treated with lenalidomide compared to those receiving dexamethasone, thalidomide-dexamethasone or VAD. A similar trend was seen in those mobilized with chemotherapy and G-CSF. A trend was seen towards decreased PBSC yield with increasing duration of lenalidomide therapy as well as increasing age (P=0.002). There was no effect on quality of PBSC collected based on similar engraftment across all groups. We recommend collection of PBSC within 6 months of initiation of therapy with lenalidomide containing regimens to minimize the risk of mobilization failures.

Indexed as

Hematopoietic Stem Cell MobilizationHematopoietic Stem Cell TransplantationAdultAgedAngiogenesis InhibitorsAntineoplastic AgentsAntineoplastic Agents, HormonalAntineoplastic Combined Chemotherapy ProtocolsCombined Modality TherapyDexamethasoneDoxorubicinFemaleHumansLenalidomideMaleMiddle AgedAngiogenesis InhibitorsAntineoplastic AgentsAntineoplastic Agents, HormonalDexamethasoneDoxorubicinLenalidomideThalidomideVincristine

Identifiers

PMID17581613
OpenAlexW2036985459

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.